Patents by Inventor Ester Fernandez-Salas

Ester Fernandez-Salas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD39 antibodies and use thereof
    Patent number: 11970543
    Abstract: Provided herein are anti-CD39 antibodies that inhibit the enzymatic activity of human CD39 and methods of using the same.
    Type: Grant
    Filed: March 2, 2023
    Date of Patent: April 30, 2024
    Assignees: ARCUS BIOSCIENCES, INC., WUXI BIOLOGICS IRELAND LIMITED
    Inventors: Christine Elizabeth Bowman, Ada Pei Xian Chen, Ester Fernandez-Salas, Nigel Pelham Clinton Walker, Xiaoning Zhao, Yaohua Hu, Siwei Nie, JijIe Gu
  • ANTI-CD39 ANTIBODIES AND USE THEREOF
    Publication number: 20240034803
    Abstract: Provided herein are anti-CD39 antibodies that inhibit the enzymatic activity of human CD39 and methods of using the same.
    Type: Application
    Filed: March 2, 2023
    Publication date: February 1, 2024
    Applicants: ARCUS BIOSCIENCES, INC., WUXI BIOLOGICS IRELAND LIMITED
    Inventors: Christine Elizabeth Bowman, Ada Pei Xian Chen, Ester Fernandez-Salas, Nigel Pelham Clinton Walker, Xiaoning Zhao, Yaohua Hu, Siwei Nie, Jijie Gu
  • CELLS USEFUL FOR IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
    Publication number: 20230323290
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Application
    Filed: August 9, 2022
    Publication date: October 12, 2023
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. Jacky, D. Dianne Hodges, Ester Fernandez-Salas
  • IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
    Publication number: 20230279083
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Application
    Filed: September 29, 2022
    Publication date: September 7, 2023
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina Wong, D. Dianne Hodges, Kei Roger Aoki
  • FORMULATIONS OF BIOLOGICS FOR INTRAVESICAL INSTILLATION
    Publication number: 20230256063
    Abstract: Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed.
    Type: Application
    Filed: September 16, 2022
    Publication date: August 17, 2023
    Inventors: Eric A. Forssen, Patrick M. Hughes, David C. Rupp, Terrence J. Hunt, Gary Shimizu, Joseph Francis, Ron S. Broide, Ester Fernandez-Salas, Catherine Rheaume
  • IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
    Publication number: 20230235031
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Application
    Filed: August 17, 2022
    Publication date: July 27, 2023
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina Wong, D. Dianne Hodges, Kei Roger Aoki
  • Fused 1,4-oxazepines as BET protein degraders
    Patent number: 11466028
    Abstract: The present disclosure provides compounds represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: October 11, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Yang Hu, Chong Qin, Fuming Xu, Jiantao Hu, Bing Zhou, Zhuo Chen, Ester Fernandez-Salas, Longchuan Bai, Donna McEachern
  • IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF
    Publication number: 20220227778
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are EED inhibitors. EED inhibitors are useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: July 16, 2020
    Publication date: July 21, 2022
    Inventors: Shaomeng Wang, Rohan Rej, Changwei Wang, Mi Wang, Jianfeng Lu, Chao-Yie Yang, Ester Fernandez-Salas, Jeanne Stuckey
  • Immuno-based botulinum toxin serotype A activity assays
    Patent number: 11332518
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: May 17, 2022
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina Wong, D. Dianne Hodges, Kei Roger Aoki
  • IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
    Publication number: 20220144925
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Application
    Filed: January 11, 2022
    Publication date: May 12, 2022
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina Wong, D. Dianne Hodges, Kei Roger Aoki
  • BET bromodomain protein degraders with cleavable linkers
    Patent number: 11267822
    Abstract: The present disclosure provides compounds represented by Formula (I): Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Y, ?, Ar, W, L, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I)I for use to treat a condition or disorder responsive to inhibition and/or degradation of BET bromodomains such as cancer.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: March 8, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Weiguo Xiang, Fuming Xu, Longchuan Bai, Ester Fernandez-Salas, Donna McEachern
  • Immuno-based botulinum toxin serotype A activity assays
    Patent number: 11261240
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: March 1, 2022
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina Wong, D. Diane Hodges, Kei Roger Aoki
  • IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
    Publication number: 20210340229
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Application
    Filed: July 15, 2021
    Publication date: November 4, 2021
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton Garay, Lina S. Wong, D. Diane Hodges, Kei Roger Aoki
  • FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS
    Publication number: 20210284657
    Abstract: The present disclosure provides compounds represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
    Type: Application
    Filed: September 13, 2017
    Publication date: September 16, 2021
    Inventors: Shaomeng Wang, Yang Hu, Chong Qin, Fuming Xu, Jiantao Hu, Bing Zhou, Zhuo Chen, Ester Fernandez-Salas, Longchuan Bai, Donna McEachern
  • IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
    Publication number: 20210171614
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Application
    Filed: December 17, 2020
    Publication date: June 10, 2021
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton Garay, Lina S. Wong, D. Diane Hodges, Kei Roger Aoki
  • IMMUNO-BASED RETARGETED ENDOPEPTIDASE ACTIVITY ASSAYS
    Publication number: 20210172952
    Abstract: The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.
    Type: Application
    Filed: January 25, 2021
    Publication date: June 10, 2021
    Inventors: Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Fernandez-Salas
  • CELLS USEFUL FOR IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
    Publication number: 20210163887
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Application
    Filed: January 13, 2021
    Publication date: June 3, 2021
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. Jacky, D. Hodges, Ester Fernandez-Salas
  • Immuno-based retargeted endopeptidase activity assays
    Patent number: 10900967
    Abstract: The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: January 26, 2021
    Assignee: Allergan, Inc.
    Inventors: Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Fernandez-Salas
  • IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
    Publication number: 20200392212
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Application
    Filed: July 2, 2020
    Publication date: December 17, 2020
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton Garay, Lina S. Wong, D. Dianne Hodges, Kei Rogers Aoki
  • IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
    Publication number: 20200369749
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Application
    Filed: July 2, 2020
    Publication date: November 26, 2020
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton Garay, Lina S. Wong, D. Dianne Hodges, Kei Rogers Aoki